The scale is finally moving. Clothes fit differently. Then something else shows up: the stairs feel harder, a bag of groceries feels heavier, and getting out of a low chair takes a push from the armrest.
Weight loss on semaglutide or tirzepatide can change a life. Not every pound that leaves the scale is fat. Some of it is lean tissue. How much you keep depends heavily on what you do while the weight is coming off.
Why lean tissue leaves with the weight
GLP-1 medicines work mainly on appetite and satiety signaling. They quiet hunger, slow how quickly the stomach empties, and make eating less feel manageable. That is a different job from restoring sex hormones or thyroid function, which is why these medicines and hormone care can sit side by side in a plan without competing. I covered that relationship in GLP-1 and Hormone Optimization Aren't Competing Treatments.
When you eat less for months, your body draws on stored energy. Most of it comes from fat. Some comes from lean tissue, which includes muscle along with organs, connective tissue, and water. This happens with nearly any meaningful weight loss, medication or not. What GLP-1s change is the scale: they help people lose far more weight, far faster, than diet alone usually allows. More total weight lost means more total lean tissue in play.
Thyroid hormone shifts on GLP-1 therapy are a separate story, covered in The Weight Comes Back for Two Reasons Nobody Warns You About. This post is about body composition and strength.
What the body-composition studies show
The clearest verified numbers come from SURMOUNT-1, the pivotal tirzepatide trial (Jastreboff et al., 2022). In a substudy of 160 participants who had DXA body-composition scans, people on tirzepatide lost an average of 21.3% of their body weight, 33.9% of their fat mass, and 10.9% of their lean mass over 72 weeks. About 75% of the weight lost was fat and about 25% was lean. The placebo group, losing a smaller amount through lifestyle changes alone, showed the same 75/25 split (Look et al., 2025).
That detail reframes the conversation. The medication did not make weight loss unusually costly to lean tissue. It produced much more weight loss, in the same proportions that lifestyle weight loss produces.
In STEP 1, the pivotal semaglutide trial, DXA scans in 140 participants told a similar story. Lean mass fell in absolute terms, but because fat mass fell further, the proportion of lean mass relative to total body mass went up (Wilding et al., 2021).
Across the wider set of GLP-1 based trials, results vary. In some studies lean tissue made up about 15% or less of the weight lost. In others it reached 40 to 60%, depending on the population, the drug, and how body composition was measured (Neeland, Linge, and Birkenfeld, 2024).
A DXA "lean mass" number is not a muscle number. It includes muscle along with organs, fluid, and even the water held inside fat tissue. Losing lean mass on a scan is not the same as losing that much muscle.
Muscle quality, function, and who needs extra attention
MRI, which can measure muscle more directly, adds an encouraging layer. On GLP-1 therapy, the loss in muscle volume generally matches what the weight loss itself would predict, and the muscle that remains tends to carry less fat inside it. Better insulin sensitivity likely contributes. Reviewers describe these changes as largely adaptive, with improved muscle quality lowering the odds of losing strength and function (Neeland, Linge, and Birkenfeld, 2024).
Function data point the same direction. In STEP 1, people taking semaglutide were more likely than those on placebo to report a clinically meaningful improvement in physical functioning (Wilding et al., 2021).
So the concern is not that everyone on a GLP-1 is headed toward frailty. The risk concentrates in specific situations. Reviewers point to older age and more severe illness (Neeland, Linge, and Birkenfeld, 2024). In my practice I also watch closely when someone starts with less muscle, loses weight very quickly, or has appetite so suppressed that protein and training slip without anyone noticing. In those settings, sarcopenia (progressive loss of muscle mass and strength) is a real risk worth planning around from the start (Neeland, Linge, and Birkenfeld, 2024).
What protects lean tissue
Two things carry the strongest evidence, and they work best together: resistance training and enough protein.
Resistance training is the signal that tells muscle it is still needed. A 2025 meta-analysis of 25 randomized trials in adults losing weight through diet found that adding resistance exercise protected fat-free mass and increased fat loss, with a strength benefit supported by lower-certainty evidence (Binmahfoz et al., 2025). Those trials studied diet-driven weight loss in adults up to age 65, not GLP-1 therapy specifically, and trials pairing GLP-1s with structured training are still emerging. The direction of the evidence is consistent enough to act on now.
Protein is the raw material. Across 49 trials of healthy adults doing resistance training, protein supplementation improved gains in muscle and strength, with little added benefit above roughly 1.6 grams per kilogram of body weight per day. The benefit also got smaller with age (Morton et al., 2018). That figure comes from training research in healthy adults, so treat it as context rather than a personal target. Kidney function, total calories, and how much you can comfortably eat on the medication all shape the right number for you.
Protein alone is not a shortcut. In a trial of adults aged 55 to 80 on a weight-loss diet, a modestly higher protein intake did not significantly preserve fat-free mass by itself. The group that combined higher protein with resistance exercise was the only one to gain fat-free mass within the study, although the difference between groups did not reach statistical significance (Verreijen et al., 2017).
Obesity guidelines make the same point from another angle: medication is recommended in addition to lifestyle care, not in place of it (Grunvald et al., 2022). On a GLP-1, lifestyle has to mean more than walking and hoping a low appetite spares your muscle.
Where hormones and peptides fit
Testosterone, estrogen, and the growth hormone axis all influence muscle biology, and for someone with a true deficiency, restoring them can belong in a complete plan. That is a different claim from saying hormone therapy or a growth hormone-releasing peptide will prevent lean loss on semaglutide or tirzepatide. I'm not aware of trials that test that directly, and drugs designed specifically to protect muscle alongside GLP-1 therapy are still in development (Neeland, Linge, and Birkenfeld, 2024). When symptoms and labs point to a deficiency, it deserves evaluation on its own merits. It does not replace training and protein.
A familiar pattern
A patient in their early fifties started a weekly GLP-1 and lost a substantial amount of weight over several months. The number on the scale was a win. But stairs had started to feel harder, legs felt softer, and a simple sit-to-stand test in the office took more effort than it should have. Appetite had dropped so far that protein intake had drifted down without anyone noticing.
We did not treat it as the medication failing. We treated it as a quality-of-weight-loss problem. Resistance training went on the calendar as a fixed appointment. Protein became a daily target instead of an afterthought, built into the first meal of the day when appetite was strongest. Hormone labs were checked because the symptoms justified it. Strength and ease of movement became part of every follow-up, right alongside the scale. Over the following months the weight kept coming off, and the stairs got easier.
That is why I want the lean and strength conversation at the start of GLP-1 care, not after the engine has already shrunk.
What to track, and when
The scale tells you how much weight is leaving. It does not tell you what kind. Ideally before starting a GLP-1, or as early as possible after, establish a baseline: a body-composition measurement such as a DXA scan where available, plus simple strength checks like grip strength and a timed sit-to-stand. Repeating those every few months while weight is actively coming off shows whether strength is holding as the pounds drop.
Strength usually responds to consistent training within weeks, well before muscle size changes on a scan, which makes those simple checks a useful early signal. A food log for a week or two, focused on protein, often reveals how far intake has drifted once appetite quiets.
In the pivotal trials, most weight loss played out over roughly a year to a year and a half. That is a long stretch to go without anyone checking strength. If strength is slipping while the scale drops, that is a signal to revisit the plan with your prescriber: training, protein, the pace of weight loss, and the medication itself.
The goal is to keep the fat loss and protect the strength that carries you through your day. GLP-1 therapy can be the right tool and still deserve a plan for what leaves the scale.
Where to take this next
If you are already a patient at a 4Ever Young clinic, take this information to your clinic team. Talk with the clinical staff who already know you and your history. I support that care.
If you are not located near a 4Ever Young clinic and would like a conversation with me virtually, email me at drwilcox@precisionhormoneconsulting.com to request a free virtual consultation. Virtual consultations are available in Texas, Arizona, Florida, Oregon and Colorado.
Darrell Wilcox, MD | @wellnessdoc_4everyoung on Instagram
Wellness Doc ยท 4Ever Young
Sources
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024.
Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. PMID: 39996356.
Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26 Suppl 4:16-27. PMID: 38937282.
Binmahfoz A, Dighriri A, Gray C, Gray SR. Effect of resistance exercise on body composition, muscle strength and cardiometabolic health during dietary weight loss in people living with overweight or obesity: a systematic review and meta-analysis. BMJ Open Sport Exerc Med. 2025. PMID: 40909191.
Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. Br J Sports Med. 2018;52(6):376-384. PMID: 28698222.
Verreijen AM, Engberink MF, Memelink RG, et al. Effect of a high protein diet and/or resistance exercise on the preservation of fat free mass during weight loss in overweight and obese older adults: a randomized controlled trial. Nutr J. 2017;16(1):10. PMID: 28166780.
Grunvald E, Shah R, Hernaez R, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022;163(5):1198-1225. PMID: 36273831.
This content is for educational purposes only and does not constitute medical advice. GLP-1 medications require a prescription and ongoing medical monitoring, and protein and exercise targets should be individualized, particularly for anyone with kidney disease or other chronic conditions. Hormone and lab decisions deserve individualized evaluation with a licensed clinician who knows your history. Individual results vary, and no outcome is guaranteed. Dr. Wilcox is licensed to practice in Texas, Arizona, Colorado, Oregon, and Florida.
